Loading clinical trials...
Loading clinical trials...
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type A (AGN-151607) Injections Into the Epicardial Fat Pads to Prevent Post-Operative Atrial Fibrillation in Patients Undergoing Open-Chest Cardiac Surgery
Conditions
Interventions
AGN-151607
Placebo
Locations
32
United States
Stanford University School of Med /ID# 236922
Stanford, California, United States
Yale New Haven Hospital - Yale School of Medicine /ID# 238221
New Haven, Connecticut, United States
Medstar Washington Hospital Center /ID# 234322
Washington D.C., District of Columbia, United States
Emory Saint Joseph's Hospital /ID# 234334
Atlanta, Georgia, United States
Lutheran Medical Group /ID# 237990
Fort Wayne, Indiana, United States
Ochsner Medical Center /ID# 238004
New Orleans, Louisiana, United States
Start Date
March 1, 2019
Primary Completion Date
March 24, 2022
Completion Date
March 6, 2023
Last Updated
May 14, 2024
Lead Sponsor
AbbVie
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions